Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Int J Neurosci. 2020 Apr 7:1–7. doi: 10.1080/00207454.2020.1746309

Table 1.

Demographic and clinical characteristics

Variable PD (n = 19) Healthy controls (n =
10)
p-
value
Age (years) 66.6 ± 8.9 65.3 ± 7.3 .70
Sex (female/male, n) 5/14 7/3 .03*
Education (years) 17.5 ± 2.8 17.3 ± 3.9 .84
Handedness (R/L, n) 19/0 10/0 N/A
Cognitive status (MoCA score) 27.3 ± 1.4 27.6 ± 2.3 .69
Disease duration (years) 5.7 ± 3.0 N/A N/A
MDS-UPDRS II 11.5 ± 6.8 N/A N/A
MDS-UPDRS III 30.9 ± 11.5 N/A N/A
Modified H & Y scale 2.1 ± .4 N/A N/A
LED 749.3 ± 370.9 N/A N/A
SCOPA-AUT 15.5 ± 6.6 N/A N/A

Note: PD = Parkinson’s disease; R/L = Right/Left; MoCA = Montreal Cognitive Assessment; MDS-UPDRS = Movement Disorder Society Unified Parkinson Disease Rating Scale; H &Y = Hoehn and Yahr; LED = Levodopa Equivalent Dose; SCOPA-AUT = Scales for Outcomes in Parkinson's Disease-Autonomic questionnaire; N/A = Not Applicable. The results are presented as mean ± standard deviation except for the sex variable.

*

Significant value (p < .05).